Heart Tech Gets Major Upgrades

Inflo Health's new suite specifically targets care management gaps for three prevalent and costly conditions: Abdominal Aortic Aneurysm (AAA), Heart Failure, and Coronary Artery Calcification (CAC). The platform acts as a "diagnostic care orchestration" layer, integrating with electronic health records to ensure that once a condition is detected, the patient completes all necessary follow-up steps. The standard for in-clinic cardiac diagnosis is the 12-lead ECG, which provides a comprehensive 12-angle view of the heart's electrical activity. Most at-home monitors are limited to a single-lead or 6-lead view, offering less detailed information. HeartBeam's technology aims to bridge this gap by synthesizing a clinical-grade 12-lead view from a more user-friendly device. HeartBeam's system, which recently received FDA 510(k) clearance for its synthesis software, uses a portable, credit-card-sized device with five sensors instead of the usual ten electrodes. The company's first commercial partner, the preventive cardiology practice ClearCardio, will roll out the technology to its members for arrhythmia assessment. HeartBeam plans a limited market launch in early 2026 and is also pursuing a specific FDA indication for heart attack detection. Atrial fibrillation (AFib) is associated with a five-fold increased risk of stroke. The primary stroke prevention treatments include lifelong oral anticoagulant medications (blood thinners), which carry a risk of major bleeding, and surgical procedures to close the left atrial appendage (LAA), a small pouch where clots often form. Current LAA closure devices are pre-shaped and can sometimes fail to create a perfect seal against the heart wall, leading to leaks that compromise their effectiveness. The magnetic gel offers a potential solution by being an injectable fluid that can conform to the unique anatomy of any patient's appendage, creating a complete and personalized closure. The novel procedure involves guiding the magnetic fluid into the left atrial appendage via a catheter. An external magnetic field is used to hold the fluid in place against the heart's blood flow until it interacts with the blood and hardens into a flexible gel. Over time, the heart's own tissue is expected to heal over the gel implant. This magnetic gel technology has so far been tested successfully in rats and pigs, with animals showing no clot formation or other ill effects. In one case, a pig remained healthy for two years after the procedure. Researchers caution, however, that many more years of testing are required before this technique could be trialed in humans.